NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Coulter I, Hardy M, Shekelle P, et al. Best-Case Series for the Use of Immuno-Augmentation Therapy and Naltrexone for the Treatment of Cancer. Rockville (MD): Agency for Healthcare Research and Quality (US); 2003 Apr. (Evidence Reports/Technology Assessments, No. 78.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Best-Case Series for the Use of Immuno-Augmentation Therapy and Naltrexone for the Treatment of Cancer

Best-Case Series for the Use of Immuno-Augmentation Therapy and Naltrexone for the Treatment of Cancer.

Show details


  1. Adler S R, Foskett J R. Disclosing complementary and alternative medicine use in the medical encounter: A qualitative study in women with breast cancer. J Fam Pract. 1999;48:453–458. [PubMed: 10386489]
  2. Angell M, Kassirer P. Alternative medicine: The risks of untested and unregulated remedies. N Engl J Med. 1998;339:839–841. [PubMed: 9738094]
  3. Astin J A. Why patients use alternative medicine: Results of a national study. JAMA. 1998;279:1548–1553. [PubMed: 9605899]
  4. Beckrow K, Wyatt G, Given C. et al. Complementary therapy use among older cancer patients. Support Care Cancer. 1999;7:172. (abstr O-36)
  5. Begbie S D, Kerestes Z L, Bell D R. Patterns of alternative medicine use by cancer patients. Med J Aust. 1996;165:545–548. [PubMed: 8941239]
  6. Bihari B. Naltrexone's mechanism in cancer treatment. Paper, 1999, personal communication.
  7. Bihari B. Low dose naltrexone and cancer. Paper, not dated, personal communication.
  8. Bihari B, Ottomanelli GA, Orbe MG, et al. Low dose Naltrexone in the treatment of Acquired Deficiency Syndrome. Oral Presentation at the IV International AIDS Conference in Stockholm, June 1988. Personal communication.
  9. Boon H, Stewart M, Kennard M. et al. Use of complementary/alternative medicine by breast cancer survivors in Ontario: Prevalence and perceptions. J Clin Oncol. 2000;18(13):2515–2521. [PubMed: 10893281]
  10. Bourgeault I. Physicians' attitudes toward patients' use of alternative cancer therapies. Can Med Assoc J. 1996;155:1679–1685. [PMC free article: PMC1335492] [PubMed: 8976333]
  11. Burstein H J, Gelber S, Guadagnoli E. et al. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999;340:1773–1739. [PubMed: 10352166]
  12. Campion E W. Why unconventional medicine? N Engl J Med. 1993;328:282–283. [PubMed: 8418412]
  13. Cassileth B R. Unorthodox cancer medicine. Cancer Invest. 1986;4:591–598. [PubMed: 3548915]
  14. Cassileth B R, Lusk E J, Guerry D. et al. Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med. 1991;324:1180–1185. [PubMed: 2011162]
  15. Cassileth B R, Lusk E F, Strouse T B. et al. Contemporary unorthodox treatments in cancer medicine: A study of patients, treatments, and practitioners. Ann Intern Med. 1984;101:105–112. [PubMed: 6732073]
  16. Center for Alternative Medicine Research in Cancer website. Immune-augmentation therapy. immune.htm, 1999.
  17. Coppes M J, Anderson R A, Egeler R M. et al. Alternative therapies for the treatment of childhood cancer. N Engl J Med. 1998;339:846–847. [PubMed: 9750078]
  18. Coss R A, McGrath P, Caggiano V. Alternative care: Patient choices for adjunct therapies within a cancer center. Cancer Pract. 1998;6:176–181. [PubMed: 9652249]
  19. DiPaola R S, Zhang H, Lambert G H. et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 1998;339:785–791. [PubMed: 9738085]
  20. Eisenberg D M, Davis R B, Ettner S L. et al. Trends in alternative medicine use in the United States, 1990-1997: Results of a followup national survey. JAMA. 1998;280:1569–1575. [PubMed: 9820257]
  21. Ernst E, Cassileth B R. The prevalence of complementary/alternative medicine in cancer. A systematic review. Cancer. 1998;83:777–782. [PubMed: 9708945]
  22. Faw C, Ballentine R, Ballentine L. et al. Unproved cancer remedies: A survey of use in pediatric outpatients. JAMA. 1978;238:1536–1538. [PubMed: 578224]
  23. IAT Cancer Clinic website., 2001.
  24. Lerner I J, Kennedy B J. The prevalence of questionable methods of cancer treatment in the United States. CA Cancer J Clin. 1992;42:181–191. [PubMed: 1568137]
  25. Levin J S, Glass T A, Kushi L H. et al. Quantitative methods in research on complementary and alternative medicine: A methodological manifesto. Med Care. 1997;35:1079–1094. [PubMed: 9366888]
  26. McGinnis L S. Alternative therapies, 1990: An overview. Cancer. 1991;67:1788–1793. [PubMed: 2001579]
  27. National Cancer Institute website. Immuno-augmentative therapy cancer facts,, 1999.
  28. Neogi T, Oza A M. Use of alternative medicine: Are we failing in our communication with patients? A study assessing psychosocial impact of alternative medicine on cancer patients. Proc Am Soc Clin Oncol. 1998;17:416a. (abstr 1604)
  29. Office of Technology Assessment website. Unconventional cancer treatments. ~ota/disk2/1990/9044/904408.PDF, 1990.
  30. Paltiel O, Avitzour M, Peretz T. et al. Determinants of use of complementary therapies by patients with cancer. J Clin Oncol. 2001;19(9):2439–2448. [PubMed: 11331323]
  31. Richardson M, Sanders T, Palmer L. et al. Complementary/alternative medicine use in comprehensive cancer center and implications for oncology. J Clin Oncol. 2000;18(13):2505–2514. [PubMed: 10893280]
  32. Richardson M A, Ramirez T, Nanney K. et al. Alternative/complementary medicine: Implications for patient-provider communication. Proc Am Soc Clin Oncol. 1999;18:590a. (abstr 2279)
  33. Schipper The Functional Living Index-Cancer: Development and validation. J Clin Oncol. 1994;2:472–483. [PubMed: 6374052]
  34. Sparber A, Bauer L, Curt G. et al. Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum. 2000;27(6):887–888. [PubMed: 10833691]
  35. US House Select Committee on Aging: Quackery: A $10 billion scandal. 98th Congress, second session, May 31, 1984.
  36. White CL. One year later: “One pill a day keeps some cancers at bay.” An update on the low-dose naltrexone story. Paper,2000, personal communication.
Bookshelf ID: NBK36959
PubReader format: click here to try


  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...